Lilly Antibody Drug Fails In COVID-19 Study

U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to help. Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look found no safety problem but a low chance that the drug would prove helpful for hospitalized patients. President Donald Trump received a similar drug when he was sickened earlier this month.